Secretome Analysis of Mesenchymal Stem Cell Factors Fostering Oligodendroglial Differentiation of Neural Stem Cells In Vivo by Samper Agrelo, Iria et al.
  
Int. J. Mol. Sci. 2020, 21, 4350; doi:10.3390/ijms21124350 www.mdpi.com/journal/ijms 
Article 
Secretome Analysis of Mesenchymal Stem Cell 
Factors Fostering Oligodendroglial Differentiation  
of Neural Stem Cells In Vivo 
Iria Samper Agrelo 1, Jessica Schira-Heinen 1, Felix Beyer 1,2, Janos Groh 3, Christine Bütermann 1, 
Veronica Estrada 1, Gereon Poschmann 4, Ana Bribian 5, Janusz J. Jadasz 1,  
Laura Lopez-Mascaraque 5, David Kremer 1, Rudolf Martini 3, Hans Werner Müller 1,  
Hans Peter Hartung 1, James Adjaye 6, Kai Stühler 4,7,† and Patrick Küry 1,†,* 
1 Department of Neurology, Medical Faculty, Heinrich-Heine-University, D-40225 Düsseldorf, Germany; 
iria.samperagrelo@med.uni-duesseldorf.de (I.S.A.); j.schira@uni-duesseldorf.de (J.S.-H.); fel.beyer@fau.de 
(F.B.); christine.buetermann@med.uni-duesseldorf.de (C.B.); veronica.estrada@uni-duesseldorf.de (V.E.); 
janusz.jadasz@uni-duesseldorf.de (J.J.J.); david.kremer@med.uni-duesseldorf.de (D.K.); 
hanswerner.mueller@uni-duesseldorf.de (H.W.M.); hans-peter.hartung@uni-duesseldorf.de (H.P.H.) 
2 Institute for Biochemistry, University of Erlangen-Nürnberg, 91054 Erlangen, Germany 
3 Department of Neurology, Section of developmental neurobiology, University Hospital Würzburg,  
D-97080 Würzburg, Germany; groh_J@ukw.de (J.G.); rudolf.martini@mail.uni-wuerzburg.de (R.M.) 
4 Institute for Molecular Medicine, Proteome Research, Medical Faculty, Heinrich-Heine-University,  
D-40225 Düsseldorf, Germany; gereon.poschmann@uni-duesseldorf.de (G.P.);  
kai.stuehler@uni-duesseldorf.de (K.S.) 
5 Departamento de Neurobiología Molecular, Celular y del Desarrollo, Instituto Cajal-CSIC,  
28002 Madrid, Spain; abribian@gmail.es (A.B.); mascaraque@cajal.csic.es (L.L.-M.) 
6 Institute for Stem Cell Research and Regenerative Medicine, Medical Faculty, Heinrich-Heine-University, 
Düsseldorf, D-40225 Germany; james.adjaye@med.uni-duesseldorf.de 
7 Molecular Proteomics Laboratory (MPL), Biologisch-Medizinisches Forschungszentrum (BMFZ), 
Heinrich-Heine-University, D-40225 Düsseldorf, Germany 
* Correspondence: kuery@uni-duesseldorf.de; Tel.: +49-211-81-17822; Fax: +49-211-81-18469 
† These authors contributed equally to this work. 
Received: 25 May 2020; Accepted: 16 June 2020; Published: 18 June 2020 
Abstract: Mesenchymal stem cell (MSC)-secreted factors have been shown to significantly promote 
oligodendrogenesis from cultured primary adult neural stem cells (aNSCs) and oligodendroglial 
precursor cells (OPCs). Revealing underlying mechanisms of how aNSCs can be fostered to 
differentiate into a specific cell lineage could provide important insights for the establishment of 
novel neuroregenerative treatment approaches aiming at myelin repair. However, the nature of 
MSC-derived differentiation and maturation factors acting on the oligodendroglial lineage has not 
been identified thus far. In addition to missing information on active ingredients, the degree to 
which MSC-dependent lineage instruction is functional in vivo also remains to be established. We 
here demonstrate that MSC-derived factors can indeed stimulate oligodendrogenesis and myelin 
sheath generation of aNSCs transplanted into different rodent central nervous system (CNS) 
regions, and furthermore, we provide insights into the underlying mechanism on the basis of a 
comparative mass spectrometry secretome analysis. We identified a number of secreted proteins 
known to act on oligodendroglia lineage differentiation. Among them, the tissue inhibitor of 
metalloproteinase type 1 (TIMP-1) was revealed to be an active component of the MSC-conditioned 
medium, thus validating our chosen secretome approach. 
Keywords: neural stem cells; mesenchymal stem cells; transplantation; oligodendroglia; glial fate 
modulation; myelin; spinal cord; secretome; TIMP-1 
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1. Introduction 
In demyelinating diseases of the central nervous system (CNS), such as multiple sclerosis, 
myelin repair activities can be observed on the basis of recruitment, activation, and differentiation of 
resident precursor and stem cells [1]. Besides oligodendroglial precursor cells (OPCs), multipotent 
adult neural stem cells (aNSCs) located in the subventricular zone (SVZ) or the dentate gyrus of the 
hippocampus serve as an additional source for the generation of myelinating oligodendrocytes [2–
7]. Yet, their regeneration capacity and overall degree of remyelination remains limited, which is 
likely a result of multiple extrinsic and intrinsic inhibitory factors [8–14]. Moreover, immune 
reactions and damaged tissues create an overall hostile environment, which further limits 
regeneration activities [15]. Insights into the underlying mechanisms on how aNSCs can be 
stimulated to differentiate into a specific cell lineage could therefore pave the way for novel 
neuroregenerative treatment approaches, which are still representing a clinically unmet need. 
Mesenchymal stem cells (MSCs) are known for their immune-modulatory capacity and can also 
mediate a number of regenerative responses [16]. Regarding the restricted repair potential of the 
adult CNS, rodent and human MSCs as well as their secreted factors have repeatedly been shown to 
promote oligodendrogenesis from aNSCs and OPCs [16–20]. The corresponding factors are likely 
secreted or shedded, and their identification might therefore provide important information on how 
existing limitations regarding successful myelin repair might be overcome. However, the nature of 
MSC-derived differentiation and maturation factors acting on the oligodendroglial lineage have not 
been disclosed thus far [21] and might therefore to be deciphered by sophisticated strategies such as 
mass spectrometry-based secretome analysis [22]. Although MSC secretome and proteome data 
already exist, most of them deal with their anti-inflammatory properties [23–25]. In addition to the 
missing information on active ingredients, it also remains to be demonstrated to what degree 
MSC-dependent lineage instruction is functional in vivo. 
In the present study, we demonstrate that mesenchymal stem cell factors can indeed stimulate 
aNSC-derived oligodendrogenesis in different CNS regions and we furthermore provide insights 
into the underlying mechanisms as we conducted a comparative secretome and proteome analyses. 
We identified several secreted proteins, many of which have unknown roles in the glial context. 
However, the analysis also revealed a group of proteins that were previously shown to act on 
oligodendroglia. 
2. Results 
2.1.Survival of MSC-CM-Stimulated aNSC In Vivo 
Mesenchymal stem cell secreted factors were shown to stimulate aNSCs towards an 
oligodendrogenic differentiation by yet unknown mechanisms [17,19,20]. To investigate the 
potential of rat MSC-conditioned medium (MSC-CM) stimulated aNSCs to generate 
oligodendroglial cells, we performed in vivo cell transplantations into different CNS tissues. Before 
transplantation experiments were initiated, we pre-treated green fluorescent protein 
(GFP)-expressing aNSCs were with either control α-minimum essential medium containing 10% 
fetal calf serum (α-MEM/10% FCS) or MSC-CM, and tested for the expression of oligodendroglial 
markers after 1, 3, and 7 days in vitro. These analyses revealed a significant increase (up to 15%) in 
the number of GFP-positive cells upon incubation in both media over time (Figure S1). In addition, a 
significantly increased number of cells expressing oligodendroglial markers was observed after 
MSC-CM stimulation, whereas astrocytic marker expression was decreased in MSC-CM-treated 
aNSCs compared to control medium-treated cells (Figure S1), thus reproducing 
MSC-CM-dependent effects previously shown in non-transfected cells [20]. 
To investigate to what degree MSC-CM-stimulated aNSCs differentiate and integrate within 
different brain environments, we performed transplantations into either grey (GM) or white matter 
(WM) regions of young adult mouse brains as previously described [26]. Moreover, we tested 
different MSC-CM stimulation periods prior to transplantation. We first monitored to what extent 
GFP-expressing cells survive after transplantation and to what level stimulation with either control 
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α-MEM or with MSC-CM affects cell survival in vivo. Transplantation into the grey (cortex) and 
white (corpus callosum) matter of the mouse brain revealed that transplanted aNSCs survived up to 
7 days post-grafting, independent of their pre-stimulation (duration and condition). In addition, 
more GFP-positive cells were found after 4 days compared to 7 days post-transplantation (pt). A 
3-day MSC-CM pre-stimulation period appeared to confer a slight survival benefit compared to the 
1-day pre-treatment (Figure 1). Additionally, no significant differences were observed when cell 
survival between grey and white matter sites were compared (Figure S2). Our analysis also revealed 
that the survival rate of transplanted aNSCs decreased as nearly no GFP-positive cells were found at 
14 days post-transplantation (data not shown). 
 
Figure 1. Survival rate of green fluorescent protein (GFP)-expressing cells after transplantation into 
the mouse brain. (A) Immunohistochemical staining was used to identify transplanted GFP-positive 
adult neural stem cells (aNSCs) (green) at 4 and 7 days post-transplantation (pt) into the mouse 
brain. aNSCs were pre-stimulated (ps) for either 1 or 3 days (1d ps and 3d ps, respectively) with 
α-minimum essential medium (α-MEM) or mesenchymal stem cell (MSC)-conditioned medium 
(MSC-CM). Representative pictures were taken from white (corpus callosum) / grey (cortex) matter 
implantation sites. (B) Quantitative evaluation of the total number of GFP-positive cells per slide 
including both grey and white matter. Statistical significance was calculated using a two-way 
ANOVA with Bonferroni posttest: * p ≤ 0.05. Data were generated on the basis of the following 
animal numbers (n): 1d ps and 4d pt, α-MEM and MSC-CM n = 4; 3d ps and 4d pt, α-MEM n = 5 and 
MSC-CM n = 4; 1d ps and 7d pt, α-MEM and MSC-CM n = 3; 3d ps and 7d pt, α-MEM and MSC-CM n 
= 4. 
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2.2. MSC-Derived Factors Promoted the Oligodendroglial Differentiation Process In Vivo 
We next investigated the differentiation capacity of transplanted aNSCs after 4 and 7 days in 
the mouse brain. To this end, we examined expression of markers for OPCs, oligodendrocytes, and 
astrocytes in GFP-positive cells. MSC-CM pre-treatment led to an increase in neural/glial antigen 2 
(NG2)-positive cells after 4 and 7 days compared to aNSCs that were pre-stimulated with α-MEM, 
(Figure 2A,A’,F,F’). Importantly, the degree of NG2 induction was similar between cells that were 
only stimulated for 1 day and for cells stimulated for 3 days (compare grey bars in Figure 2A’,F’). 
Likewise similar induction rates were observed for further markers along the oligodendroglial 
lineage such as oligodendrocyte transcription factor 2 (Olig2) (Figure 2B,B’,G,G’), 
glutathione-S-transferase-π (GSTπ) (Figure 2C,C’,H,H’), and myelin basic protein (MBP) (Figure 
2D,D’,I,I’) at both investigated time points. Similar to the observed differentiation kinetics of 
cultured aNSCs [20], accumulation of oligodendroglial markers was accompanied by a MSC-CM 
dependent decrease of glial fibrillary acidic protein (GFAP)-positive cells (Figure 2E,E’,J,J’). When 
the differentiation capacity of transplanted cells in grey and white matter was compared, no 
significant difference was observed (Figure S3). Our data therefore indicate that a 1-day long 
pre-stimulation with MSC-derived factors is sufficient to boost the oligodendroglial differentiation 
process of aNSCs after transplantation in vivo. However, for practical reasons, we continued using a 
3-day pre-stimulation period for aNSCs to be implanted into spinal cords. 
 
Figure 2. MSC-CM pre-stimulated aNSCs differentiated into mature myelin basic protein 
(MBP)-expressing oligodendrocytes after transplantation into the mouse brain. (A-E) Representative 
images of control (α-MEM) and MSC-CM pre-stimulated and transplanted GFP-positive aNSCs 
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expressing neural/glial antigen 2 (NG2) (A), oligodendrocyte transcription factor 2 (Olig2) (B), 
glutathione-S-transferase-π (GSTπ) (C), MBP (D), or glial fibrillary acidic protein (GFAP) (E) 4 days 
after transplantation into the brain. Quantification of transplanted cells expressing NG2 (A’), Olig2 
(B’), GSTπ (C’), and MBP (D’) revealed a significantly increased number of cells expressing 
oligodendroglial markers after 4 days, whereas the degree of GFAP-positive cells (E’) was 
significantly decreased. The same effects were observed at 7 days post-transplantation (F-J) with the 
corresponding quantifications shown for NG2 (F’), Olig2 (G’), GSTπ (H’), MBP (I’), and GFAP (J’). 
For statistical analysis, a two-way ANOVA with Bonferroni posttest was used: * p ≤ 0.05, ** p ≤ 0.01, 
*** p ≤ 0.001, MSC-CM compared to the respective α-MEM control (1- or 3-day pre-stimulation). 
Arrows point to GFP-positive cells (green) expressing the respective markers (red). Blue nuclei 
represent 4´,6-diamidin-2-phenylindol (DAPI) staining. Animal numbers (n): 3-5. 
2.3. Extended Survival Time of MSC-CM Pre-Stimulated aNSCs Transplanted into the Adult Rat Spinal Cord 
To evaluate the survival rate of MSC-CM pre-stimulated aNSCs and their differentiation 
potential after transplantation into other CNS tissues, we transplanted MSC-CM stimulated aNSCs 
into the grey or white matter of adult rat spinal cords. In this regard, 3-day pre-stimulated aNSCs 
were analyzed at 14 and 28 days after transplantation in order to monitor tissue integration, cell fate 
acquisition, maturation stages, and myelination capacities. 
To evaluate the survival rate of transplanted cells, we counted the number of GFP-positive cells 
per slide and animal at both time points. Quantification of transplanted cells revealed that after 14 
days the white matter environment exerted a general survival benefit on implanted cells. 
Furthermore, in both grey as well as white matter regions, fewer MSC-CM-stimulated cells 
compared to control (α-MEM)-stimulated cells were observed (Figure 3A,B). However, at the later 
time point (28 days), we observed no treatment difference in the white matter, while in the grey 
matter, MSC-CM pre-stimulated cells dominated over control (α-MEM)-treated cells. 
 
Figure 3. Survival rate of rat aNSCs after transplantation into the rat spinal cord. (A) Representative 
images of GFP-positive transplanted cells 14 and 28 days post-transplantation (pt) either in white or 
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grey matter of the rat spinal cord. Corresponding quantifications of GFP-positive cells per slide (a 
mean of three sections per slide) and animal in white and grey matter at 14 days (B) and 28 days (C). 
Statistical significance was calculated using a two-way ANOVA with Bonferroni posttest: * p ≤ 0.05, 
*** p ≤ 0.001 (for comparison between control α-MEM to MSC-CM) and ### p ≤ 0.001 (for comparison 
between white and grey matter and respective transplantation paradigm). Animal numbers (n): 14 
days pt α-MEM n = 4 and MSC-CM n = 5, 28 days pt α-MEM n = 6 and MSC-CM n = 4. 
Investigating the differentiation capacity and maturation of spinal cord-transplanted cells 
confirmed an enhanced oligodendroglial cell fate upon MSC-CM pre-stimulation at 14 and 28 days 
post-transplantation. Although no impact of MSC-CM pre-stimulation on the degree of 
Olig2-positive cells was observed (Figure 4A,A’), the degree of GSTπ-positive and MBP-positive 
cells was strongly boosted upon MSC-CM pre-treatment at both time points (Figure 4B,B’,C,C’). 
Similar to the brain-transplanted cells, this increase in oligodendrogenesis was accompanied by an 
MSC-CM-dependent decrease in GFAP positivity among GFP-positive cells (Figure 4D,D’). This 
pro-oligodendroglial behavior did not substantially differ between WM- and GM-transplanted cells 
(Figure 4E-L). In addition, a potential neuronal differentiation capacity was tested by means of 
neuronal nuclei antigen (NeuN) and neurofilament (NF) immunohistochemical staining. No 
GFP/NeuN or GFP/NF-positive cells were found under both conditions (α-MEM or MSC-CM 
pre-stimulation) and at both time points (Figure S4). These data therefore confirmed a strong 
pro-oligodendroglial effect exerted by MSC-derived factors and at the same time revealed increased 
numbers of surviving and integrated cells in the spinal cord. 
 
Figure 4. Accumulation of oligodendroglial characteristics in spinal cord-transplanted aNSCs. 
Representative pictures of GFP-positive cells expressing Olig2 (A), GSTπ (B), MBP (C), and GFAP 
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(D) at 14 and 28 days post-transplantation and following α-MEM or MSC-CM pre-treatment. The 
corresponding quantifications (percentage of expressing cells over total number of GFP-expressing 
cells) are depicted in (A’) for GFP/Olig2- in (B’) for GFP/GSTπ-, in (C’) for GFP/MBP-, and in (D’) for 
GFP/GFAP-positive cells. (E-L) Quantification and distribution of transplanted GFP-positive cells 
pre-treated with α-MEM and MSC-CM within white matter (WM) and grey (GM) at 14 and 28 days 
post-transplantation. Statistical significance was calculated using a two-way ANOVA with 
Bonferroni posttest: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 (for comparison between control α-MEM to 
MSC-CM). Arrows point to GFP-positive cells (green) expressing the respective marker proteins 
(red). Blue nuclei represent DAPI staining. Animal numbers (n): 4-6. 
2.4. MSC-CM Pre-Stimulation Enabled aNSCs to Myelinate Axons In Vivo 
In order to analyze the functionality of MBP-expressing cells and to identify myelinated 
segments, we performed co-staining for neurofilament and contactin-associated protein (Caspr), a 
marker for paranodal axonal regions of nodes of Ranvier, after 14 days of cell transplantation into rat 
spinal cords as previously established for other stem cell transplantation approaches [27,28]. 
Immunohistochemical staining revealed that processes of transplanted GFP/MBP-double positive 
cells pre-stimulated with α-MEM or MSC-CM often aligned with neurofilament-positive axons 
(Figure 5A). Triple staining for GFP, MBP, and Caspr revealed that processes of GFP/MBP-positive 
cells abutted at Caspr-positive paranodal regions (Figure 5B,B’’). Importantly, such myelinated 
segments and nodal structures were only observed at MSC-CM pre-treated NSCs, thus providing 
strong evidence that mesenchymal factors contribute to the generation of myelinated segments in 
vivo. Moreover, ultrastructural analysis of transplanted MSC-CM pre-treated cells by means of 
immunoelectron microscopy (as established in [26]; transplanted cells were identified by 
chromogenic anti-GFP immunohistochemistry resulting in dark precipitates), demonstrated that 
these cells established myelin sheaths around axons (Figure 5C) and also revealed 
GFP-immunoreactive signals in paranodal loops (Figure 5C’). 
 
Figure 5. MSC-CM pre-treated aNSCs were able to generate myelinated segments. (A) 
Representative pictures of MBP-/GFP-/neurofilament-stained spinal cord sections at 14 days 
post-transplantation. For both α-MEM and MSC-CM pre-treated and transplanted cells, we observed 
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an alignment of MBP-positive segments with neurofilament (NF)-positive axons (arrows). Nuclei are 
depicted in white. (B) MBP-positive processes of MSC-CM pre-stimulated cells often ended in 
Caspr-positive paranodes (arrows). Nuclei are depicted in white. Higher magnifications are depicted 
in (B’) for α-MEM and in (B’’) for MSC-CM pre-stimulated aNSCs. (C) Representative electron 
micrograph of a GFP-positive cells (asterisk: nucleus) 14 days post-transplantation. Chromogenic 
GFP-immunoreactivity (dark precipitate) identified myelinating processes (arrows). (C’) GFP 
expression was also detectable in the cytoplasm of paranodal loops (arrows). 
2.5. Characterization of Adult Rat Mesenchymal Stem Cell Secretome 
Despite several approaches to identify active components, the underlying mechanism and 
acting factors of MSC-mediated pro-oligodendroglial effects is still unknown. In order to shed light 
onto the composition of active proteins in the MSC secretome and to identify MSC secreted 
pro-oligodendroglial proteins, we performed a mass spectrometry-based secretome analysis (Figure 
6). For mass spectrometry analysis, MSCs and corresponding conditioned media were harvested 
after incubation with serum-free N2-medium for 48h. Proteins of four independent replicates were 
processed and analyzed with liquid chromatography–mass spectrometry (LC–MS/MS; Figure 6A). 
Secretomes were compared to corresponding proteomes in order to identify bona fide secreted 
proteins and subtract potential contaminations from dying cells due to higher abundances in the 
secretome (Figure 6B; Table S1) (according to [29]). Thus, from the total number of proteins (691 
proteins) identified in MSC-CM, we detected 152 proteins as bona fide secreted due to the 
comparison with the cellular proteome (Figure 6C; Table S1). From all secreted proteins, 85% of the 
proteins were predicted to have a signal peptide assigning them to the classical secretory pathway, 
7% exhibited a transmembrane domain, and 1% were presumably unconventionally secreted 
proteins (Figure 6D). Categorical enrichment analysis revealed that bona fide secreted proteins were 
associated with extracellular components such as the laminin complex (enrichment factor (EF) 11.4, 
p-value 6.50 x 10-4), the proteinaceous extracellular matrix (EF 10.3, p-value 5.6 x 10-18), the 
extracellular matrix (EF 8.9, p-value 3.3 x 10-30), and extracellular space (EF 7.2, p-value 8.8 x 10-25) 
(Figure 6E), whereas categories related to intracellular compartments such as the nucleus (EF -3.0, 
p-value 4.7 x 10-6), the macromolecular complex (EF -4.3, p-value 1.2 x 10-16), and the 
ribonucleoprotein complex (EF -12.0, p-value 7.8 x 10-8) were under-represented (Figure 6E). 
Furthermore, MSC-secreted proteins were associated with biological processes related to 
extracellular compartments such as the extracellular matrix organization (EF 7.9, p-value 1.0 x 10-15), 
cell adhesion (EF 5.5, p-value 5.9 x 10-18), and locomotion (EF 2.7, p-value 7.4 x 10-4) (Figure 6F), 
whereas proteins related to intracellular processes such catabolic processes (EF -5.2, p-value 1.4 x 
10-6) and translation (EF -12, p-value 2.6 x 10-3) were under-represented. We further analyzed these 
152 proteins regarding a pro-oligodendroglial fate choice (Table 1). According to the already 
described functions, several proteins identified in the MSC secretome can either directly or indirectly 
be implicated in oligodendroglial differentiation or myelination. This includes, for example, 
extracellular matrix proteins such as laminin subunit beta-2 (Lamb2), tissue inhibitor of 
metalloproteinase inhibitor type 1 (TIMP-1), dystroglycan (Dag1), aggrecan (Acan), or bone 
morphogenetic protein (BMP)-associated proteins such as chordin (Chrd) and metalloendopeptidase 
(BMP-1). Moreover, growth factors acting as possible negative regulators such as connective tissue 
growth factor (CTGF) and insulin-like growth factor-binding proteins (IGFBP). 
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Figure 6. Characterization of the mesenchymal stem cell secretome. (A) Workflow for preparation of 
MSC-derived proteomes and secretomes for quantitative LC–MS/MS analysis. (B) Heatmap of 
proteins quantified in the MSC secretome and proteome revealed a high similarity between the 
proteome samples that clearly differed from the secretomes (grey = proteins were not identified). (C) 
Volcano plot showing proteins found to be enriched in the MSC-derived secretome (152 
secretome-enriched proteins, shown as red dots on right side) and the proteome (left side, black 
dots). (D) Out of the 152 proteins found to be enriched in the secretome, 85% of them were predicted 
to have a signal peptide, 7% were transmembrane proteins, and 1% were unconventionally secreted 
(UPS). (E) Gene Ontology (GO) enrichment analysis of cellular component revealed that these 
proteins were associated with extracellular space and matrix localization. (F) GO enrichment analysis 
of biological process revealed an association with extracellular matrix organization and cell adhesion 
(5% false discovery rate (FDR)). 
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2.6. Neutralization of TIMP-1 Diminished the Pro-Oligodendroglial Effect of MSC-CM  
Proteins found to be enriched in the MSC secretome included tissue inhibitor of 
metalloproteinase type 1 (TIMP-1), which represents a promising candidate protein with known 
pro-oligodendroglial properties [42,43,50]. In order to validate our protein identification approach, 
we performed specific TIMP-1 antibody blocking assays on cultured aNSCs. To this end, we applied 
the antibody to α-MEM and MSC-CM for 1h prior to application of aNSCs. For further control, no 
antibody (normal control) and immunoglobulin G (IgG) isotype control antibody was applied. After 
3 days of culture, we determined the degree of 2′,3′-cyclic-nucleotide 3′-phosphodiesterase 
(CNPase)-positivity among aNSCs. Neutralization of TIMP-1 in MSC-CM resulted in a significantly 
reduced number of CNPase-positive cells compared to untreated (control) MSC-CM, as well as to 
IgG antibody control-treated MSC-CM (Figure 7). After TIMP-1 neutralization, we further 
demonstrated that the number of GFAP-positive cells tended to increase compared to normal 
control and IgG antibody controls (Figure 7C). To exclude intrinsic TIMP-1 antibody effects, we also 
used a series of unconditioned α-MEM, which revealed no TIMP-1 or IgG control antibody effects on 
CNPase expression or GFAP-positive cells.  
 
Figure 7. Blocking the tissue inhibitor of metalloproteinase type 1 (TIMP-1) in MSC-CM reduced its 
pro-oligodendroglial activity on cultured aNSCs. Representative immunocytochemical staining of 
2′,3′-cyclic-nucleotide 3′-phosphodiesterase (CNPase)- (A) and GFAP-positive (B) cells treated either 
with control (no antibody), anti-TIMP-1, or immunoglobulin G (IgG) control pre-incubated with 
α-MEM or MSC-CM after 3 days in culture. (C) Quantification of CNPase- and GFAP-positive (D) 
cell numbers. Number of experiments n = 4. Statistical significance was calculated using a two-way 
ANOVA with Bonferroni posttest: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. 
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3. Discussion 
In demyelinating diseases, neural stem cells can be actively recruited for myelin repair [1,3–7]. 
However, despite of their ability to differentiate into oligodendrocytes, the extent of regeneration 
and remyelination in the adult CNS remains limited [11–13]. Thus, insights into the underlying 
mechanisms on how aNSCs can be fostered to differentiate into a specific cell lineage could help in 
establishing neuroregenerative treatment approaches, which are still a clinically unmet need. 
Forthcoming strategies could include the biological or pharmacological manipulation of endogenous 
aNSCs or, under specific circumstances, also the transplantation of aNSCs previously primed to 
acquire oligodendroglial cell fates. This second approach would nevertheless be restricted to 
well-described white matter lesions. However, in an experimental set-up, site-directed cell 
transplantation might indeed provide valuable information on how stem cells can be modulated and 
placed specifically in order to regenerate oligodendrocytes and white matter. Previous studies 
demonstrated that rodent and human MSC-secreted factors promote oligodendroglial 
differentiation of aNSCs in vitro [17,19,20,51]. However, the degree to which MSC-dependent 
lineage instruction is functional in vivo remains to be demonstrated. Moreover, the nature of 
MSC-derived differentiation factors regarding oligodendroglial lineage differentiation remain 
elusive thus far [21]. 
3.1. Enhanced Oligodendroglial Differentiation of MSC-CM-Stimulated aNSCs In Vivo 
Our present study revealed that aNSC transplanted into different CNS tissues are able to 
survive at least up to 28 days post-grafting, independent of their pre-treatment. As expected, cell 
survival was diminished over time, which could depend on the immune response since the animals 
were not immune-suppressed as in other studies [52–54]. In comparison to the brain, the spinal cord 
environment appeared to provide a better survival rate. In this regard, it should be noted that this 
difference might also derive from rat cells being implanted into mouse brains, which could cause 
additional immune responses. Given that mouse neural stem cells have thus far not been shown to 
respond adequately to MSC-derived factors (own observations), we could not apply a direct 
comparison using a mouse-to-mouse transplantation scheme. 
In the brain, grey and white matter can differently affect OPC differentiation [55], and we 
previously showed that white matter localization promotes differentiation towards myelinating 
oligodendrocytes at the expense of astrocyte generation when transplanted aNSC were depleted 
from the intrinsic oligodendrogenesis inhibitor p57kip2 [26]. However, in both studies, regional 
differences of the brain showed no impact on cell survival, which was confirmed by the 
here-described brain transplantation experiments. While transplantation of aNSCs into grey or 
white matter of the brain showed no difference in survival, most of the transplanted cells were found 
in white matter after spinal cord transplantation. It therefore appears that spinal cord white matter 
constitutes a preferred region for transplanted cells, which is in agreement with previous 
observations [56].  
More importantly, our experiments clearly revealed that MSC-derived factors can indeed boost 
the generation of oligodendrocytes in vivo while preventing an astrocytic cell fate. Whereas such a 
directed stimulation depends on at least 3 days of pre-stimulation in cultured cells [20], our current 
results demonstrate that the pro-oligodendroglial effect in vivo can be equally well seen after a 1-day 
pre-treatment period. It thus appears that such an initial MSC-dependent stimulation of 
oligodendrogenesis is dominant and the corresponding impulse can be maintained in the CNS 
environment. 
Besides the predominant expression of oligodendroglial markers, we only noticed myelin 
sheath generation in the spinal cord in response to pre-stimulation with mesenchymal-derived 
factors, indicating that not only quantitative but also qualitative effects are mediated. Myelin sheath 
generation was revealed by the presence of paranodal Caspr signals in close apposition to 
MBP-positive processes of MSC-CM pre-stimulated and transplanted cells [27,28]. Furthermore, 
representative examination of MSC-CM pre-stimulated cells by immunoelectron microscopy 
revealed myelinating processes ending in paranodal loops. This is furthermore supported by the 
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observation that, at late time points, MSC-CM pre-treated aNSCs were more frequently observed in 
CNS tissues as these cells might have better survived due to successful tissue integration and axon 
ensheathment. Note that the generation of quantitative data on node formation and myelination is 
out of scope of this study and must be addressed in future investigations. 
Although we detected more mature oligodendrocytes in response to MSC-CM, we found there 
was no difference in the number of Olig2-expressing cells, possibly reflecting the fact that 
Olig2-positivity, although differing in its subcellular distribution, is also featured by astrocytic cells 
[57]. 
The here-observed pro-oligodendroglial features within the almost healthy CNS (disregarding 
injection sites) suggest that similarly treated aNSCs might also be able to promote myelin repair 
upon injury and demyelination, also in light of the increased number of naked axons to be contacted. 
In addition, transplanted cells could also have an impact on endogenous progenitor or stem cells by 
direct cell–cell contact or by secretion of trophic factors, thus promoting endogenous remyelination 
capacity and functional regeneration. However, such experiments were out of the scope for the 
current analysis, but will be conducted in the future through applying toxin- as well as 
immune-mediated demyelination models. 
3.2. MSCs Secreted a Number of Oligodendroglial Regulatory Proteins 
Underlying pro-oligodendroglial mechanisms and proteins secreted by MSCs have not yet been 
deciphered in detail. Although some MSC secretome or proteome data already exist, most of them 
deal with anti-inflammatory, regenerative, and tumor-promoting properties of MSCs [23–25,58–60]. 
Therefore, we applied a quantitative secretome approach for the analysis of MSC-derived proteins 
with pro-oligodendroglial activity. From the initially identified 691 proteins, we determined 152 
proteins (Table S1) as bona fide secreted due to the significant enrichment in MSC-CM. GO term 
enrichment analysis further confirmed that these proteins are mainly localized in the extracellular 
environment and predominantly involved in extracellular matrix (ECM) organization and cell 
adhesion. Moreover, in order to find pro-oligodendroglial factors, we further analyzed these 152 
proteins regarding a pro-oligodendroglial fate choice (Table 1). On the basis of their previously 
shown impact on oligodendrogenesis, we identified first obvious promising candidates, among 
them ECM proteins such as Lamb2. Laminins were previously shown to be important for CNS 
myelination [61], and pericyte-dependent stimulation of aNSC-dependent oligodendrogenesis was 
recently found to depend on the related protein laminin subunit alpha 2 (Lama2) [62]. Laminins 
regulate CNS myelination by interacting with integrin receptors and by binding to the non-integrin 
ECM receptor dystroglycan [34], which was also enriched in the MSC secretome, possibly acting on 
OPC proliferation via its intracellular cleaved part [33]. Another bona fide secreted protein with a 
known pro-oligodendroglial function is chordin. As a BMP antagonist, it can promote 
oligodendrogenesis from SVZ neural stem cells [31], and we previously found chordin to be induced 
in response to the pro-oligodendroglial suppression of the p57kip2 inhibitor [63]. Furthermore, we 
detected syntenin-1, known to regulate OPC migration via interaction with NG2 [47]. While proteins 
such as dystroglycan and chordin promote proliferation and differentiation, prosaposin, also known 
as sulfated glycoprotein 1, promotes expression of myelin constituents and protects myelinating 
glial cells [45,46]. Protecting properties have also been assigned to the arrest-specific protein 6 (Gas6) 
[36], and its deficiency increases oligodendrocyte loss during cuprizone-induced demyelination [64]. 
Besides pro-oligodendroglial proteins, we also identified proteins inhibiting oligodendroglial 
differentiation such as metalloendopeptidase BMP 1 [41], thrombospondin 1 [48], and tenascin C 
[49]. An equilibrated action of positive and negative regulators might be necessary for a timed and 
successful cell fate acquisition, thereby contributing to successful establishment of new myelin 
sheaths. On the other hand, future studies will show whether blocking such proteins could also 
increase the efficiency of the MSC-CM treatment. 
Finally, one of the most promising candidate proteins was TIMP-1, on the basis of its 
neuroprotective functions by means of matrix metalloproteinase (MMP) regulation [65] and its 
capacity to promote oligodendrocyte differentiation and myelination [42,43,50]. As we 
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demonstrated that neutralization of TIMP-1 in MSC-CM results in a significantly reduced number of 
CNPase-positive cells and an increased (non-significant) degree of GFAP-positive cells in culture, 
we provide a proof-of-principle that the chosen secretome/proteome approach is valid. Moreover, 
we demonstrated that TIMP-1 is one of the key players in MSC-mediated oligodendrocyte 
differentiation and myelination. 
Given the large number of differentiation-related proteins identified in the MSC secretome, we 
suggest that the MSC-CM effect depends on the interplay of both pro-oligodendroglial as well as 
anti-astrocytic factors possibly acting at different differentiation stages of which TIMP-1 constitutes 
one element. Upcoming experiments will therefore have to functionally investigate further protein 
candidates and also use combinations of neutralization antibodies or recombinant proteins for 
validation. Finally, given our observation that, in vivo, a much shorter instruction period by 
MSC-derived factors is sufficient for successful oligodendrogenesis, myelination, and cell 
integration, researchers should then test combinations of presumably active recombinant proteins 
on pre-stimulated aNSCs to be transplanted in vivo. 
4. Materials and Methods  
4.1. Animals  
For the isolation of rat aNSCs and MSCs, female Wistar rats (8–10 weeks old, ≈210 g) were used 
throughout the study. Transplantation experiments into wild type female mice (C57Bl/6, 13–14 
weeks old, ≈18–21g) and rats (Wistar, 10–12 weeks old, between 210 and 230 g) were all approved by 
the LANUV (Landesamt für Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen; Az.: 
84-02.04.2015.A239; Az.: 84-02.04.2015.A525) and carried out in accordance with ethical care. All 
rodents were housed in a pathogen-free facility with 12 h light/dark cycle, and were supplied with 
food/water ad libitum. 
4.2. Mesenchymal Stem Cell Culture 
Preparation and cultivation of adult rat mesenchymal stem cells (MSCs) were performed as 
previously described [19,20]. For experiments, we cultured bone marrow-derived rat MSCs for 3 to 4 
days in α-MEM/10% FBS (both Gibco Cell Culture, Life Technologies, Karlsruhe, Germany) 
containing 1% penicillin–streptomycin (Gibco) until reaching a confluent cell layer (90–100%). 
Afterwards, medium was changed and cells were cultured in α-MEM/10% FBS for another 3 to 4 
days. The corresponding supernatant was filtered (0.2 µm filtropur S filter; Sarstedt AG and Co. KG, 
Nümbrecht, Germany) and used as rat mesenchymal stem cell-conditioned medium (MSC-CM) for 
aNSC stimulation. MSCs were used from passage 3 to 10. 
4.3. Adult Rat Neural Stem Cell Culture and Transfection 
Preparation and cultivation of aNSC derived from the rat subventricular zone (SVZ) were 
conducted as previously described [20,63]. SVZ-derived aNSCs were resuspended in neurobasal 
(NB) medium (Gibco) containing B27 (Gibco), 2 mM L-glutamine (Gibco), 1% penicillin–
streptomycin (Gibco) supplemented with 2 mg/mL heparin (Sigma-Aldrich Chemie GmbH, 
Steinheim, Germany), 20 ng/mL fibroblast growth factor 2 (FGF-2; R&D Systems, 
Wiesbaden-Nordenstadt, Germany), and 20 ng/mL epidermal growth factor (EGF; R&D Systems, 
Wiesbaden-Nordenstadt, Germany), from here on referred to as NBall medium. For experiments, 
aNSCs were seeded with a cell number of 1 x 106 cells in 1 T75 culture flask in 10 mL NBall medium 
and cultured for 7 days at 37 °C in a humidified incubator with 5% CO2. The medium was exchanged 
twice a week, and on day 7, we passaged aNSCs using accutase (PAA Laboratories, Pasching, 
Austria) for separation (10-15 min at 37 °C). For differentiation, we seeded aNSC on acid-pretreated 
and poly-L-ornithine/laminin (100 µg/mL and 12 µg/mL, respectively, both Sigma-Aldrich Chemie 
GmbH)-coated 13 mm glass cover slips (6.3 x 104 cells per coverslip). Cells were cultured for 24 h in 
NBall medium before changing to differentiation control medium (α-MEM/10% FBS) or MSC-CM. 
For cell visualization of transplanted cells, we co-transfected aNSC with the UbC-StarTrack 
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plasmids pCMV-hyPBase and UbC-EGFP [66] using the rat neural stem cell nucleofector kit (Lonza, 
Basel, Switzerland), as described previously [20]. Transfected cells were seeded with a concentration 
of 3 x 106 cells in 1 T75 culture flask in 10 mL NBall medium and were cultured for 7 days at 37 °C in 
a humidified incubator with 5% CO2. Two or four days before transplantation, we seeded aNSCs on 
poly-L-ornithine/laminin (100 µg/mL and 12 µg/mL, Sigma-Aldrich Chemie GmbH)-coated Petri 
dishes (35 x 10 mm) for 24 h in NBall medium before changing to control α-MEM/ 10% FBS or 
MSC-CM. 
4.4. Antibody Blocking and Immunocytochemistry 
For blocking experiments, we seeded aNSCs on acid-pretreated and 
poly-L-ornithine/laminin-coated glass cover slips (5 x 104 cells per coverslip) and cultured in NBall 
medium for 24 h. To neutralize metallopeptidase inhibitor 1 (TIMP-1), we incubated MSC-CM with 
an anti-rat TIMP-1 antibody (25 µg/mL, R&D System, AF580) for 1h at 37 °C, prior to application to 
aNSCs. Isotype control IgG antibody (25 µg/mL, R&D System, AB-108-C) was used as control. In 
addition, we also applied both antibodies to normal control medium (α-MEM / 10% FCS) in order to 
exclude unspecific antibody effects. After 3 days (blocking experiments) or 1–7 days 
(PiggyBac-transfected aNSC differentiation) of incubation with α-MEM / 10% FCS or MSC-CM, we 
fixed aNSCs using 4% paraformaldehyde (PFA) and subjected them to immunocytochemical 
staining, as previously described [20]. After primary antibodies were blocked of unspecific binding 
sites and permeabilized for 45 min in 1% normal goat serum (NGS; Sigma-Aldrich Chemie GmbH) 
and 0.1% Triton in phosphate-buffered saline (PBS), we incubated them in 1% NGS (in PBS, 0.03% 
Triton) at 4 °C overnight. The following antibodies were used: rabbit anti-glial fibrillary acidic 
protein (GFAP; 1:4000, DAKO Agilent, Santa Clara, CA, USA; research resource identifiers (RRID): 
AB_10013382), mouse anti-2′,3′-cyclic-nucleotide 3′-phosphodiesterase (CNPase; 1:500, Biolegend, 
San Diego, CA, USA; RRID: AB_2565362), chicken anti-green fluorescent protein/citrine (GFP; 
1:2000; Aves Labs, Tigard, OR, US; RRID: AB_10000240), rabbit anti-neural/glial antigen 2 (NG2; 
1:100; Merck Millipore, Burlington, MA, USA; RRID: AB_11213678, 1h RT), and rat anti-myelin basic 
protein (MBP; 1:250, Bio-Rad Laboratories, Inc., Hercules, CA, USA; RRID: AB_325004). Primary 
antibody incubation was followed by 3 washing steps with PBS and incubation with secondary 
(anti-mouse and anti-rabbit) antibodies conjugated with either Alexa Fluor594 or Alexa Fluor488 
(1:500; Thermo Fisher Scientific, Darmstadt, Germany) in 1% NGS (in PBS, 0.03% Triton) 
supplemented with 4’,6-diamidin-2-phenylindol (DAPI, 0.02 µL/mL; Roche Diagnostic GmbH, 
Mannheim, Germany) at room temperature for 90 min. Cells were mounted with Citifluor (Cilifluor, 
Leicester, United Kingdom) and images were taken using a Zeiss Axioplan2 microscope (Carl Zeiss 
AG, Jena, Germany). For quantitative analyses, we used ImageJ Software (National Institute of 
Health (NIH) USA) [67,68] to count the positive cells that were normalized to the total cell number 
(DAPI-positive cells). For statistical analysis, we applied two-way analysis of variance (ANOVA) 
with Bonferroni posttest by using GraphPad Prism 5.0c software. 
4.5. Stereotactic Cell Transplantations 
Rat aNSCs were detached with accutase and kept at room temperature in their respective 
media. For transplantation into the mouse brain, aNSCs were centrifuged for 5 min at 140 × g, 
washed once in PBS, and were finally resuspended in PBS to a concentration of 1 x 105 cells/µL. The 
transplantation procedure was performed as previously described [26]. Briefly, recipient C57Bl/6J 
mice were deeply anesthetized using isoflurane or sevoflurane inhalation. The skull was exposed 
using a scalpel, and holes were drilled at 0.7 mm (anterior–posterior), ± 1 mm (medial–lateral). 
Approximately 0.75 µL of the cell suspension was injected in the white (corpus callosum) and grey 
(cortex) matter of the mice brains (13–14 weeks old) according to [55]. Transplantations were 
performed with a Hamilton syringe (10 µL Neuros Model 1701 RN, ga 33, L 0–20 mm) at 0.7 mm 
(anterior–posterior), ± 1 mm (medial–lateral), 2.1 to 1.8 mm (dorsal–ventral) relative to Bregma using 
a motorized robot stereotaxic instrument and StereoDrivesoftware (Neurostar, Tubingen, Germany). 
Postoperative care comprised an analgesic treatment (Rimadyl, Pfizer Deutschland GmbH, Berlin, 
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Germany; 5 mg/kg) for 3 days, starting on the day of operation. For tissue collection, mice were 
deeply anesthetized with isoflurane and transcardially perfused with 20 mL cold PBS followed by 20 
mL 4% PFA. Mouse brains were post-fixed overnight in 4% PFA at 4 °C, followed by 24 to 48 h 
cryoprotective dehydration in 30% sucrose (in PBS) at 4 °C. Brains were embedded in Tissue-Tek 
OCT (Sakura Finetek Europe, Netherlands), frozen, and stored at -80 °C until preparation of 10 µm 
sections using a cryostat (Leica CM3050S). Sections were stored at -80 °C.  
For spinal cord transplantations, adult female rats were treated as previously described [26,69] 
with slight modifications. Briefly, rat aNSC transplantation was performed at thoracic level 8 (Th8) 
using a Hamilton syringe (10 µL Neuros Model 1701 RN, ga 33, L 0-20 mm) attached to a Small 
Animal Stereotaxic Instrument (David Kopf Instruments, Tujunga, CA, USA). Injections were 
performed at 0.1 mm lateral to the midline and 1.1 to 0.8 mm dorsal–ventral from the dural surface. 
At each transplantation site, we slowly and within 4 min injected 1 µL of either 1 x 105 control 
α-MEM pre-stimulated (3 day) or MSC-CM pre-stimulated (3 days) aNSCs in PBS. Postoperative 
care included prophylactic oral antibiotic treatment (Baytril, Bayer Health Care, Leverkusen, 
Germany; 0.4 mL/kg) for 7 days and analgesic treatment (Rimadyl, Pfizer, New York, NY, USA; 5 
mg/kg) for 3 days starting, on the day of surgery. After 14 or 28 days post-operation, animals were 
deeply anesthetized using a mixed solution containing ketamine (100 mg/kg body weight) and 
xylazine (10 mg/kg body weight), and were transcardially perfused with 200 mL 4 °C ice-cold PBS 
followed by 400 mL 4% PFA. Spinal cords were harvested and post-fixed overnight in 4% PFA at 4 
°C, followed by 24 h washing in PBS and 24 to 48 h cryoprotection in 30% sucrose (in PBS) at 4 °C. 
Spinal cords were then embedded in Tissue-Tek OCT (Sakura Finetek Europe, Netherlands), frozen, 
and stored at -30 °C until preparation of 14 µm sections using a cryostat (Leica, Wetzlar, Germany, 
CM3050S). Sections were stored at -30 °C. 
4.6. Immunohistochemistry 
Immunohistochemical staining was performed as previously described [26]. Briefly, defrosted 
brain and spinal cord sections were air-dried for at least 15 min at room temperature (RT), and were 
afterwards rehydrated for 5 min in distilled water, transferred to -20 °C acetone (5 min), and washed 
in 1x tris-buffered saline (TBS) (pH 7.6) and 1x TBS-T (TBS containing 0.02% Triton) for 5 min each. 
For blocking, we used 10% biotin-free bovine serum albumin (BSA; Carl Roth, Karlsruhe, Germany, 
in TBS-T) for 30 min at RT, followed by application of the following antibodies (in 5 to 10% BSA in 
TBS) and incubation overnight: rabbit anti-oligodendrocyte transcription factor 2 (Olig2; in brain 
1:2000, in spinal cord 1:1000; Merck Millipore, Burlington, MA, USA; RRID: AB_570666, RT), rabbit 
anti-neural/glial antigen 2 (NG2; 1:100; Merck Millipore, Burlington, MA, USA; RRID: AB_11213678, 
RT), rabbit anti-glutathione-S-transferase-π (GSTπ; 1:4500; ENZO Life Sciences, GmbH, Lörrach, 
Germany; RRID: AB_10615079; 4 °C), rabbit GFAP (1:10000; DAKO Agilent, Santa Clara, CA, USA; 
RRID: AB_10013382; 4 °C), rat anti-MBP (1:500, Bio-Rad Laboratories, Inc., Hercules, CA, USA; 
RRID: AB_325004, RT or 4 °C), chicken anti-green fluorescent protein/citrine (GFP; 1:2000; Aves 
Labs, Tigard, OR, USA; RRID: AB_10000240; 4 °C or RT), mouse anti-Caspr 
(anti-Caspr/paranodin/neurexin IV, clone K65/35; 1:500; 75-001; UC Davis/NIH NeuroMab Facility, 
CA, USA; RRID: AB_10671175; 4 °C), rabbit anti-neurofilament (NF; 1:2500; Abcam, Cambridge, 
United Kingdom; RRID: AB_306298; 4°C), and rabbit anti-neuronal nuclei antigen (NeuN; 1:1000; 
Abcam, Cambridge, United Kingdom; RRID: AB_2532109; 4 °C). 
Sections were washed 2 times in TBS for 5 min and incubated with appropriate secondary 
antibodies (goat anti-chicken; goat anti-rabbit; goat anti-rat conjugated with either Alexa Fluor 594, 
488, 405, or 647; 1:200 in TBS; Thermo Fisher Scientific, Darmstadt, Germany) for 30 min at RT. DAPI 
(0.04 µl/mL; Roche Diagnostic GmbH) or RedDot 2 (1:200; Biotium, Fremont, CA, USA; cat.#: 40061) 
were included for nuclei labelling. Slices were mounted with Immu-Mount (Thermo Fisher 
Scientific, Darmstadt, Germany) and analyzed using a confocal confocal laser scanning microscopy 
(CLSM) microscope 510 (CLSM 510, Carl Zeiss AG, Oberkochen, Germany). Immunohistochemical 
staining on brain and spinal cord sections was performed using the corresponding centers of 
transplantation. An average of 25 brain sections and 13 spinal cord sections per marker and per 
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time-point were analyzed, including 3 brain slices or 2 spinal cord slices per each slide. Fluorescently 
labeled cells were counted on each picture/section, and the mean number per slide (containing 3 
brain or 2 spinal cord sections, respectively) was calculated, leading to an average value for each 
animal. 
4.7. Immunoelectron Microscopy 
Immunoelectron microscopy was performed as previously described [26], with slight 
modifications. Briefly, adult rats were perfused with 4% PFA in 1 M cacodylate buffer (Carl Roth 
GmbH + Co. KG, Karlsruhe, Germany), and spinal cords were harvested and post-fixed overnight in 
4% PFA in 1M cacodylate buffer. After post-fixation, spinal cords were washed over night in PBS 
and embedded in 6% agarose in cacodylate buffer. Coronal sections (50 µm) were cut in PBS using a 
microtome (Microm HM 650 V, Thermo Fisher Scientific, Waltham, MA, USA). Free-floating sections 
were blocked with 1% BSA in PBS and incubated with 0.1 M NaIO3 in PBS and subsequently in 5% 
dimethyl sulfoxide in PBS. Sections were incubated with rabbit anti-GFP antibody (1:100; AB3080, 
Merck Millipore, Burlington, MA, USA; RRID: AB_91337) in 1% BSA in PBS overnight at 4 °C, and 
immune reactions were subsequently visualized using a biotinylated secondary antibody 
(biotinylated goat anti-rabbit IgG; 1:50; BA-1000, Vector Laboratories, Burlingame, CA, USA; RRID: 
AB_2313606) and streptavidin–biotin–peroxidase (PK-6100, Vector Laboratories, Burlingame, CA, 
USA; RRID: AB_2336819) complex using diaminobenzidine–HCl (SK-4105, Vector Laboratories, 
Burlingame, CA, USA; RRID: AB_2336520) and H2O2. After diaminobenzidine staining, appropriate 
transplantation regions were cut, and sections were osmicated and processed for light and electron 
microscopy by dehydration and embedding in Spurr’s medium. Ultrathin sections (70 nm) were 
mounted to copper grids, counterstained with lead citrate, and investigated using a ProScan Slow 
Scan CCD camera connected to a Leo 906 E electron microscope (Zeiss, Jena, Germany) and 
corresponding software iTEM (Soft Imaging System). Transplanted cells were identified on the basis 
of GFP immunoreactivity (indicated by dark precipitates). 
4.8. Statistical Analysis of IHC and ICC 
Statistical analyses and graphs were generated using Excel and Graph-Pad Prism 5.0 software. 
To determine statistical significance in graphs with more than two conditions, we applied ordinary 
two-way analysis of variance (ANOVA) with Bonferroni posttest. Statistical significance thresholds 
were set as follows: * p < 0.05; ** p < 0.01; *** p < 0.001. All data are shown as mean values ± SEM, and 
“n” represents the number of independent experiments performed. 
4.9. Preparation of Mesenchymal Stem Cell Secretome and Proteome 
Mesenchymal stem cells were prepared, as described previously, through seeding 4 x 105 
cell/100 mm Ø culture dish in α-MEM-10% FBS until a confluent cell layer was achieved. For mass 
spectrometry analysis, we used four independent biological replicates of MSCs. Confluent MSCs 
were washed three times with PBS in order to remove the FBS and were then incubated for another 
48h in serum-free N2-medium [22,70,71] consisting of Dulbecco’s modified Eagle’s medium 
(DMEM, Gibco Cell Culture, Thermo Fisher Scientific, Darmstadt, Germany) containing 5 mg/mL 
insulin, 30 nM sodium selenite, 100 µM putrescine, 20 nM progesterone, and 5 µg/mL transferrin (all 
Sigma-Aldrich Chemie GmbH). Medium was changed again after 48 h to further exclude FBS effects, 
and was then incubated for another 48 h in N2 medium. 
To analyze secreted proteins within this second N2 medium preparation by mass spectrometry, 
we performed trichloroacetic acid (TCA) precipitation as previously described [70,71]. Briefly, 
conditioned medium was transferred to a 50 mL tube, centrifuged at 950 × g at 4 °C for 10 min, and 
filtered through a 0.2 µm filter (Pall Acrodisc). The medium was mixed with 10% sodium lauroyl 
sarcosinate (Sigma-Aldrich Chemie GmbH) up to a final concentration of 0.1%. Ice-cold 
trichloroacetic acid (Sigma-Aldrich Chemie GmbH) was added (7.5% final concentration).  The 
medium was incubated for 1 h on ice and then centrifuged at 7100 × g at 4 °C for 10 min. After 
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removing the supernatant, we resuspended the pellet in 1 mL ice-cold acetone and we then 
centrifuged it again. After removing the supernatant, we dried the pellet at room temperature and 
then dissolved it in lysis buffer consisting of 30 mM Tris base (Sigma-Aldrich Chemie GmbH), 7M 
urea (Sigma-Aldrich Chemie GmbH,), and 2 M thiourea (Sigma-Aldrich Chemie GmbH). The 
protein content was determined by Pierce 660 nm Protein Assay (Thermo Fisher Scientific). 
To analyze the corresponding cell proteome, we washed MSCs 3 times with cold PBS after 
removing the conditioned medium for secretome analysis. Afterwards, 2 mL cold PBS was added 
and cells were detached using a cell scraper. Cell suspension was transferred to a 15 mL tube and 
centrifuged with 800 × g at 4 °C for 5 min. The supernatant was removed, and cell pellets were 
immediately frozen and stored at -80 °C. MSCs were lysed by using the lysis buffer described above. 
The lysate was sonicated 6 × 10 s, centrifuged at 16000 × g for 15 min, and the protein concentration of 
the supernatant was then determined. 
For in-gel digestion, 5 µg total protein of each sample (secretomes as well as proteomes) was 
used for short SDS gel electrophoresis (5 mm running distance, 10 min) and stained with Coomassie 
brilliant blue. The resulting lanes were excised, washed, reduced with 10 mM dithiothreitol (DTT; 
Serva Electrophoresis, Heidelberg, Germany) and alkylated with 55 mM iodacetamide 
(Sigma-Aldrich Chemie GmbH). Proteins were digested with 0.1 µg trypsin (Serva Electrophoresis) 
overnight at 37°C, and peptides were extracted, dried, and finally resuspended in 0.1% 
trifluoroacetic acid. 
4.10. Liquid Chromatography and Mass Spectrometric Analysis 
Extracted peptides were separated by an Ultimate 3000 RSCLnano System (Thermo Fisher 
Scientific) with an Acclaim PepMap100 trap column (3 µm C18 particle size, 100 Å pore size, 75 µm 
inner diameter, 2 cm length, Thermo Fisher Scientific) as a precolumn using 0.1% trifluoroacetic acid 
(TFA) as a mobile phase and an Acclaim PepMapRSLC (2 µm C18 particle size, 100 Å pore size, 
75 µm inner diameter, 25 cm length, Thermo Fisher Scientific) analytical column. The flow rate for 
analytical separation was constant with 300 nL/min, and a 2 h gradient of 0.1% formic acid (Fluka) to 
0.1% formic acid/60% acetonitrile was used for peptide separation. Peptides were eluted via nano 
electrospray ionization into the mass spectrometer (Orbitrap Fusion Lumos mass spectrometer, 
Thermo Fisher Scientific) operated in positive mode with advanced peak determination enabled. 
Precursor mass spectra were recorded in the orbitrap analyzer within a mass range of 200–2000 m/z 
and a resolution of 120,000 (maximum ion time: 60 ms, automatic gain control target value: 250,000, 
profile mode). For a maximum of 2 seconds, we isolated precursors with charge states +2 to +7 and a 
minimum intensity of 5000 within a 1.6 m/z isolation window and fragmented via higher-energy 
collisional dissociation. MS/MS spectra were recorded in the linear ion trap in centroid mode with a 
maximal ion time of 50 ms and a target value for the automatic gain control was set to 10,000. The 
scan rate was “rapid”, and already fragmented precursors were excluded from further isolation for 
the next 60 s. 
4.11. Analysis of Mass Spectrometric Data 
To identify peptides and proteins, we used the MaxQuant environment (version 1.6.6.0, MPI for 
Biochemistry, Planegg, Germany). If not stated otherwise, the identification was done with standard 
parameters. Searches were performed using the rat UP000002494 proteome dataset (29,951 entries) 
downloaded on 10th April 2019 from the UniProt Knowledgebase using tryptic specificity (cleavage 
behind R and K) with a maximum of 2 missed cleavages sites. Carbamidomethylation at cysteines 
was considered as fixed, and methionine oxidation was set as variable modification. A first search 
was performed with 20 ppm precursor mass tolerance. Peptides identified with high confidence 
were then used for recalibration using the “software lock mass” feature of MaxQuant [72]. 
Thereafter, a main search was conducted with a precursor mass tolerance of 4.5 ppm. The mass 
tolerance or fragment spectrum was set to 0.5 Da. Peptides and proteins were accepted at a false 
discovery rate of 1%. The “match between runs” function was enabled as well as label-free 
quantification. 
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Corresponding secretomes and proteomes were compared to identify enriched proteins in the 
secretome, probably representing secreted proteins according to Grube et al. [29]. After a 
MaxQuant-based database search and quantification, we analyzed quantitative protein level data 
within the Perseus framework (version 1.6.6.0, MPI for Biochemistry, Planegg, Germany). Proteins 
identified only by site or marked as contaminant (from the MaxQuant contaminant list) as well as 
reverse hits were excluded. Proteins with at least 2 identified peptides and a minimum of 3 valid 
values in at least 1 group were considered. Calculations were done on normalized intensities (LFQ 
intensities), as provided by MaxQuant, and missing data were imputed before statistical analysis by 
values from a downshifted normal distribution (width 0.3 standard deviations, down-shift 1.8 
standard deviations). The significance analysis of microarrays (SAM) method [73] was applied on 
log2-transformed values using a S0 constant of 0.8 and a 5% false discovery rate-based cutoff. 
Presented fold changes were calculated as difference from mean values of log2-transformed 
intensities. 
To predict unconventionally secreted proteins, we used the OutCyte prediction tool [74], 
wherein we selected classically secreted proteins on the basis of the annotation from UniProtKB 
(signal peptide predicted, but neither a transmembrane domain nor a kdel sequence present). Gene 
Ontology (GO) biological process (GOBP) and cellular compartment (GOCC) were used for 
categorical annotations of proteins identified in the MSC-derived secretome, and annotation 
enrichments were calculated by Fisher’s exact tests. Enrichment associated p-values were adjusted 
via the method of Benjamini and Hochberg. 
4.12. Data Availability 
The mass spectrometry proteomics data were deposited to the ProteomeXchange Consortium via 
the PRIDE [75] partner repository with the dataset identifier PXD018231.  
5. Conclusions 
In the present study, we demonstrated that MSC-derived secreted factors promote 
oligodendrogenesis of aNSCs transplanted into different CNS regions. Furthermore, mass 
spectrometry-based secretome analysis provided insights into the underlying mechanisms. Our 
analysis identified several proteins previously shown to regulate oligodendrogenesis. As a 
promising protein candidate, we validated TIMP-1 to be an active component of the 
MSC-conditioned medium promoting oligodendrogenesis in vitro. Given that MSC-derived factors 
are sufficient to promote successful oligodendrogenesis, myelination and cell integration, 
transplantation of pre-stimulated aNSCs upon CNS injury, and demyelination could help to 
promote functional remyelination. 
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BMP Bone morphogenetic protein 
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Caspr Contactin-associated protein 
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CLSM Confocal laser scanning microscopy 
CNPase 2′,3′-Cyclic-nucleotide 3′-phosphodiesterase 
CNS Central nervous system 
CTGF Connective tissue growth factor 
Dag1 Dystroglycan 
DAPI 4´,6-diamidin-2-phenylindol 
DMEM Dulbecco’s modified Eagle’s medium 
DTT Dithiothreitol 
ECM Extracellular matrix 
EF Enrichment factor 
EGF Epidermal growth factor 
EM Electron microscopy 
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FDR False discovery rate 
FGF Fibroblast growth factor 
Fn Fibronectin 
Gas6 Growth arrest-specific protein 6 
GFAP Glial fibrillary acidic protein 
GFP Green fluorescent protein 
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GSTπ Glutathione-S-transferase-π 
GO Gene Ontology 
GOBP Gene Ontology biological process 
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IGFBP Insulin-like growth factor-binding protein 
IgG Immunoglobulin G 
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LC–MS/MS Liquid chromatography–mass spectrometry/mass spectrometry 
MBP Myelin basic protein 
MMP Matrix metalloproteinase 
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NF Neurofilament 
NG2 Neural/glial antigen 2 
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Olig2 Oligodendrocyte transcription factor 2 
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pt Post transplantation 
Sdcbp Syntenin-1 
SP Signal peptide 
Spp1 Osteopontin 
SVZ Subventricular zone 
TCA Trichloroacetic acid 
Thbs1 Thrombospondin 1 
TIMP-1 Tissue inhibitor of metalloproteinase type 1 
TM Transmembrane 
Tnc Tenascin c 
UPS Unconventional protein secretion 
WM White matter 
References 
1. Franklin, R.J. Why does remyelination fail in multiple sclerosis? Nat. Rev. Neurosci. 2002, 3, 705–714. 
2. Jessberger, S.; Toni, N.; Clemenson, G.D. Jr.; Ray, J.; Gage, F.H. Directed differentiation of hippocampal 
stem/progenitor cells in the adult brain. Nat. Neurosci. 2008, 11, 888–893. 
3. Akkermann, R.; Jadasz, J.J.; Azim, K.; Küry, P. Taking Advantage of Nature's Gift: Can Endogenous 
Neural Stem Cells Improve Myelin Regeneration? Int. J. Mol. Sci. 2016, 17, 1895. 
4. Nait-Oumesmar, B.; Picard-Riera, N.; Kerninon, C.; Decker, L.; Seilhean, D.; Hoglinger, G.U.; Hirsch, E.C.; 
Reynolds, R.; Baron-Van Evercooren, A. Activation of the subventricular zone in multiple sclerosis: 
Evidence for early glial progenitors. Proc. Natl. Acad. Sci. USA 2007, 104, 4694–4699. 
5. Nait-Oumesmar, B.; Picard-Riera, N.; Kerninon, C.; Baron-Van Evercooren, A. The role of SVZ-derived 
neural precursors in demyelinating diseases: From animal models to multiple sclerosis. J. Neurol. Sci. 2008, 
265, 26–31. 
6. Picard-Riera, N.; Decker, L.; Delarasse, C.; Goude, K.; Nait-Oumesmar, B.; Liblau, R.; Pham-Dinh, D.; 
Baron-Van Evercooren, A. Experimental autoimmune encephalomyelitis mobilizes neural progenitors 
from the subventricular zone to undergo oligodendrogenesis in adult mice. Proc. Natl. Acad. Sci. USA 2002, 
99, 13211–13216. 
7. Xing, Y.L.; Roth, P.T.; Stratton, J.A.; Chuang, B.H.; Danne, J.; Ellis, S.L.; Ng, S.W.; Kilpatrick, T.J.; Merson, 
T.D. Adult neural precursor cells from the subventricular zone contribute significantly to oligodendrocyte 
regeneration and remyelination. J. Neurosci. 2014, 34, 14128–14146. 
8. Charles, P.; Reynolds, R.; Seilhean, D.; Rougon, G.; Aigrot, M.S.; Niezgoda, A.; Zalc, B.; Lubetzki, C. 
Re-expression of PSA-NCAM by demyelinated axons: An inhibitor of remyelination in multiple sclerosis? 
Brain 2002, 125 Pt 9, 1972–1979. 
9. Mi, S.; Miller, R.H.; Lee, X.; Scott, M.L.; Shulag-Morskaya, S.; Shao, Z.; Chang, J.; Thill, G.; Levesque, M.; 
Zhang, M.; et al. LINGO-1 negatively regulates myelination by oligodendrocytes. Nat. Neurosci. 2005, 8, 
745–751. 
10. Mi, S.; Pepinsky, R.B.; Cadavid, D. Blocking LINGO-1 as a therapy to promote CNS repair: From concept 
to the clinic. CNS Drugs 2013, 27, 493–503. 
11. de Castro, F.; Bribian, A.; Ortega, M.C. Regulation of oligodendrocyte precursor migration during 
development, in adulthood and in pathology. Cell Mol. Life Sci. 2013, 70, 4355–4368. 
12. Kremer, D.; Aktas, O.; Hartung, H.P.; Küry, P. The complex world of oligodendroglial differentiation 
inhibitors. Ann. Neurol. 2011, 69, 602–618. 
13. Kuhlmann, T.; Miron, V.; Cui, Q.; Wegner, C.; Antel, J.; Bruck, W. Differentiation block of oligodendroglial 
progenitor cells as a cause for remyelination failure in chronic multiple sclerosis. Brain 2008, 131 Pt 7, 1749–
1758. 
14. Gruchot, J.; Weyers, V.; Göttle, P.; Förster, M.; Hartung, H.P.; Küry, P.; Kremer, D. The Molecular Basis for 
Remyelination Failure in Multiple Sclerosis. Cells 2019, 8, 825. 
15. Kotter, M.R.; Stadelmann, C.; Hartung, H.P. Enhancing remyelination in disease--can we wrap it up? Brain 
2011, 134 Pt 7, 1882–1900. 
16. Uccelli, A.; Moretta, L.; Pistoia, V. Mesenchymal stem cells in health and disease. Nat. Rev. Immunol. 2008, 
8, 726–736. 
Int. J. Mol. Sci. 2020, 21, 4350 22 of 25 
 
17. Rivera, F.J.; Couillard-Despres, S.; Pedre, X.; Ploetz, S.; Caioni, M.; Lois, C.; Bogdahn, U.; Aigner, L. 
Mesenchymal stem cells instruct oligodendrogenic fate decision on adult neural stem cells. Stem Cells 2006, 
24, 2209–2219. 
18. Kassis, I.; Grigoriadis, N.; Gowda-Kurkalli, B.; Mizrachi-Kol, R.; Ben-Hur, T.; Slavin, S.; Abramsky, O.; 
Karussis, D. Neuroprotection and immunomodulation with mesenchymal stem cells in chronic 
experimental autoimmune encephalomyelitis. Arch. Neurol. 2008, 65, 753–761. 
19. Jadasz, J.J.; Kremer, D.; Göttle, P.; Tzekova, N.; Domke, J.; Rivera, F.J.; Adjaye, J.; Hartung, H.P.; Aigner, L.; 
Küry, P. Mesenchymal stem cell conditioning promotes rat oligodendroglial cell maturation. PLoS ONE 
2013, 8, e71814. 
20. Jadasz, J.J.; Tepe, L.; Beyer, F.; Samper Agrelo, I.; Akkermann, R.; Spitzhorn, L.S.; Silva, M.E.; Oreffo, 
R.O.C.; Hartung, H.P.; Prigione, A.; et al. Human mesenchymal factors induce rat hippocampal- and 
human neural stem cell dependent oligodendrogenesis. Glia 2018, 66, 145–160. 
21. Rivera, F.J.; Kandasamy, M.; Couillard-Despres, S.; Caioni, M.; Sanchez, R.; Huber, C.; Weidner, N.; 
Bogdahn, U.; Aigner, L. Oligodendrogenesis of adult neural progenitors: Differential effects of ciliary 
neurotrophic factor and mesenchymal stem cell derived factors. J. Neurochem. 2008, 107, 832–843. 
22. Schira-Heinen, J.; Grube, L.; Waldera-Lupa, D.M.; Baberg, F.; Langini, M.; Etemad-Parishanzadeh, O.; 
Poschmann, G.; Stühler, K. Pitfalls and opportunities in the characterization of unconventionally secreted 
proteins by secretome analysis. Biochim Biophys Acta Proteins Proteom 2019, 1867, 140237. 
23. Maffioli, E.; Nonnis, S.; Angioni, R.; Santagata, F.; Cali, B.; Zanotti, L.; Negri, A.; Viola, A.; Tedeschi, G. 
Proteomic analysis of the secretome of human bone marrow-derived mesenchymal stem cells primed by 
pro-inflammatory cytokines. J. Proteomics 2017, 166, 115–126. 
24. Teixeira, F.G.; Carvalho, M.M.; Panchalingam, K.M.; Rodrigues, A.J.; Mendes-Pinheiro, B.; Anjo, S.; 
Manadas, B.; Behie, L.A.; Sousa, N.; Salgado, A.J. Impact of the Secretome of Human Mesenchymal Stem 
Cells on Brain Structure and Animal Behavior in a Rat Model of Parkinson's Disease. Stem Cells Transl Med. 
2017, 6, 634–646. 
25. Baberg, F.; Geyh, S.; Waldera-Lupa, D.; Stefanski, A.; Zilkens, C.; Haas, R.; Schroeder, T.; Stühler, K. 
Secretome analysis of human bone marrow derived mesenchymal stromal cells. Biochim Biophys Acta 
Proteins Proteom 2019, 1867, 434–441. 
26. Beyer, F.; Jadasz, J.; Samper Agrelo, I.; Schira-Heinen, J.; Groh, J.; Manousi, A.; Butermann, C.; Estrada, V.; 
Reiche, L.; Cantone, M.; et al. Heterogeneous fate choice of genetically modulated adult neural stem cells 
in gray and white matter of the central nervous system. Glia 2020, 68, 393–406. 
27. Samanta, J.; Grund, E.M.; Silva, H.M.; Lafaille, J.J.; Fishell, G.; Salzer, J.L. Inhibition of Gli1 mobilizes 
endogenous neural stem cells for remyelination. Nature 2015, 526, 448–452. 
28. Koutsoudaki, P.N.; Papastefanaki, F.; Stamatakis, A.; Kouroupi, G.; Xingi, E.; Stylianopoulou, F.; Matsas, 
R. Neural stem/progenitor cells differentiate into oligodendrocytes, reduce inflammation, and ameliorate 
learning deficits after transplantation in a mouse model of traumatic brain injury. Glia 2016, 64, 763–779. 
29. Grube, L.; Dellen, R.; Kruse, F.; Schwender, H.; Stühler, K.; Poschmann, G. Mining the Secretome of C2C12 
Muscle Cells: Data Dependent Experimental Approach To Analyze Protein Secretion Using Label-Free 
Quantification and Peptide Based Analysis. J. Proteome Res. 2018, 17, 879–890. 
30. Keough, M.B.; Rogers, J.A.; Zhang, P.; Jensen, S.K.; Stephenson, E.L.; Chen, T.; Hurlbert, M.G.; Lau, L.W.; 
Rawji, K.S.; Plemel, J.R.; et al. An inhibitor of chondroitin sulfate proteoglycan synthesis promotes central 
nervous system remyelination. Nat. Commun. 2016, 7, 11312. 
31. Jablonska, B.; Aguirre, A.; Raymond, M.; Szabo, G.; Kitabatake, Y.; Sailor, K.A.; Ming, G.L.; Song, H.; 
Gallo, V. Chordin-induced lineage plasticity of adult SVZ neuroblasts after demyelination. Nat. Neurosci 
2010, 13, 541–550. 
32. Ercan, E.; Han, J.M.; Di Nardo, A.; Winden, K.; Han, M.J.; Hoyo, L.; Saffari, A.; Leask, A.; Geschwind, D.H.; 
Sahin, M. Neuronal CTGF/CCN2 negatively regulates myelination in a mouse model of tuberous sclerosis 
complex. J. Exp. Med. 2017, 214, 681–697. 
33. Leiton, C.V.; Aranmolate, A.; Eyermann, C.; Menezes, M.J.; Escobar-Hoyos, L.F.; Husain, S.; Winder, S.J.; 
Colognato, H. Laminin promotes metalloproteinase-mediated dystroglycan processing to regulate 
oligodendrocyte progenitor cell proliferation. J. Neurochem. 2015, 135, 522–538. 
34. Colognato, H.; Galvin, J.; Wang, Z.; Relucio, J.; Nguyen, T.; Harrison, D.; Yurchenco, P.D.; 
Ffrench-Constant, C. Identification of dystroglycan as a second laminin receptor in oligodendrocytes, with 
a role in myelination. Development 2007, 134, 1723–1736. 
Int. J. Mol. Sci. 2020, 21, 4350 23 of 25 
 
35. Lourenco, T.; Paes de Faria, J.; Bippes, C.A.; Maia, J.; Lopes-da-Silva, J.A.; Relvas, J.B.; Graos, M. 
Modulation of oligodendrocyte differentiation and maturation by combined biochemical and mechanical 
cues. Sci. Rep. 2016, 6, 21563. 
36. Shankar, S.L.; O'Guin, K.; Kim, M.; Varnum, B.; Lemke, G.; Brosnan, C.F.; Shafit-Zagardo, B. Gas6/Axl 
signaling activates the phosphatidylinositol 3-kinase/Akt1 survival pathway to protect oligodendrocytes 
from tumor necrosis factor alpha-induced apoptosis. J. Neurosci. 2006, 26, 5638–5648. 
37. Kuhl, N.M.; De Keyser, J.; De Vries, H.; Hoekstra, D. Insulin-like growth factor binding proteins-1 and -2 
differentially inhibit rat oligodendrocyte precursor cell survival and differentiation in vitro. J. Neurosci. 
Res. 2002, 69, 207–216. 
38. Li, N.; Han, J.; Tang, J.; Ying, Y. IGFBP-7 inhibits the differentiation of oligodendrocyte precursor cells via 
regulation of Wnt/beta-Catenin signaling. J. Cell Biochem. 2018, 119, 4742–4750. 
39. Kim, W.K.; Kim, D.; Cui, J.; Jang, H.H.; Kim, K.S.; Lee, H.J.; Kim, S.U.; Ahn, S.M. Secretome analysis of 
human oligodendrocytes derived from neural stem cells. PLoS ONE 2014, 9, e84292. 
40. Relucio, J.; Menezes, M.J.; Miyagoe-Suzuki, Y.; Takeda, S.; Colognato, H. Laminin regulates postnatal 
oligodendrocyte production by promoting oligodendrocyte progenitor survival in the subventricular 
zone. Glia 2012, 60, 1451–1467. 
41. See, J.; Zhang, X.; Eraydin, N.; Mun, S.B.; Mamontov, P.; Golden, J.A.; Grinspan, J.B. Oligodendrocyte 
maturation is inhibited by bone morphogenetic protein. Mol. Cell Neurosci 2004, 26, 481–492. 
42. Moore, C.S.; Milner, R.; Nishiyama, A.; Frausto, R.F.; Serwanski, D.R.; Pagarigan, R.R.; Whitton, J.L.; 
Miller, R.H.; Crocker, S.J. Astrocytic tissue inhibitor of metalloproteinase-1 (TIMP-1) promotes 
oligodendrocyte differentiation and enhances CNS myelination. J. Neurosci. 2011, 31, 6247–6254. 
43. Nicaise, A.M.; Johnson, K.M.; Willis, C.M.; Guzzo, R.M.; Crocker, S.J. TIMP-1 Promotes Oligodendrocyte 
Differentiation Through Receptor-Mediated Signaling. Mol. Neurobiol. 2019, 56, 3380–3392. 
44. Selvaraju, R.; Bernasconi, L.; Losberger, C.; Graber, P.; Kadi, L.; Avellana-Adalid, V.; Picard-Riera, N.; 
Baron Van Evercooren, A.; Cirillo, R.; Kosco-Vilbois, M.; et al. Osteopontin is upregulated during in vivo 
demyelination and remyelination and enhances myelin formation in vitro. Mol. Cell Neurosci. 2004, 25, 707–
721. 
45. Meyer, R.C.; Giddens, M.M.; Coleman, B.M.; Hall, R.A. The protective role of prosaposin and its receptors 
in the nervous system. Brain Res. 2014, 1585, 1–12. 
46. Hiraiwa, M.; Campana, W.M.; Mizisin, A.P.; Mohiuddin, L.; O'Brien, J.S. Prosaposin: A myelinotrophic 
protein that promotes expression of myelin constituents and is secreted after nerve injury. Glia 1999, 26, 
353–360. 
47. Chatterjee, N.; Stegmüller, J.; Schätzle, P.; Karram, K.; Koroll, M.; Werner, H.B.; Nave, K.A.; Trotter, J. 
Interaction of syntenin-1 and the NG2 proteoglycan in migratory oligodendrocyte precursor cells. J. Biol. 
Chem. 2008, 283, 8310–8317. 
48. Lu, Z.; Kipnis, J. Thrombospondin 1--a key astrocyte-derived neurogenic factor. FASEB J. 2010, 24, 1925–
1934. 
49. Czopka, T.; von Holst, A.; ffrench-Constant, C.; Faissner, A. Regulatory mechanisms that mediate tenascin 
C-dependent inhibition of oligodendrocyte precursor differentiation. J. Neurosci. 2010, 30, 12310–12322. 
50. Jiang, P.; Chen, C.; Liu, X.B.; Pleasure, D.E.; Liu, Y.; Deng, W. Human iPSC-Derived Immature Astroglia 
Promote Oligodendrogenesis by Increasing TIMP-1 Secretion. Cell Rep. 2016, 15, 1303–1315. 
51. Steffenhagen, C.; Dechant, F.X.; Oberbauer, E.; Furtner, T.; Weidner, N.; Küry, P.; Aigner, L.; Rivera, F.J. 
Mesenchymal stem cells prime proliferating adult neural progenitors toward an oligodendrocyte fate. 
Stem Cells Dev. 2012, 21, 1838–1851. 
52. Fricker, R.A.; Carpenter, M.K.; Winkler, C.; Greco, C.; Gates, M.A.; Bjorklund, A. Site-specific migration 
and neuronal differentiation of human neural progenitor cells after transplantation in the adult rat brain. J. 
Neurosci. 1999, 19, 5990–6005. 
53. McGinley, L.M.; Kashlan, O.N.; Chen, K.S.; Bruno, E.S.; Hayes, J.M.; Backus, C.; Feldman, S.; Kashlan, 
B.N.; Johe, K.; Feldman, E.L. Human neural stem cell transplantation into the corpus callosum of 
Alzheimer's mice. Ann. Clin. Transl. Neurol. 2017, 4, 749–755. 
54. Karimi-Abdolrezaee, S.; Eftekharpour, E.; Wang, J.; Morshead, C.M.; Fehlings, M.G. Delayed 
transplantation of adult neural precursor cells promotes remyelination and functional neurological 
recovery after spinal cord injury. J. Neurosci. 2006, 26, 3377–3389. 
Int. J. Mol. Sci. 2020, 21, 4350 24 of 25 
 
55. Vigano, F.; Möbius, W.; Götz, M.; Dimou, L. Transplantation reveals regional differences in 
oligodendrocyte differentiation in the adult brain. Nat. Neurosci. 2013, 16, 1370–1372. 
56. Enomoto, M.; Shinomiya, K.; Okabe, S. Migration and differentiation of neural progenitor cells from two 
different regions of embryonic central nervous system after transplantation into the intact spinal cord. Eur. 
J. Neurosci. 2003, 17, 1223–1232. 
57. Marshall, C.A.; Novitch, B.G.; Goldman, J.E. Olig2 directs astrocyte and oligodendrocyte formation in 
postnatal subventricular zone cells. J. Neurosci. 2005, 25, 7289–7298. 
58. Jungbluth, P.; Spitzhorn, L.S.; Grassmann, J.; Tanner, S.; Latz, D.; Rahman, M.S.; Bohndorf, M.; Wruck, W.; 
Sager, M.; Grotheer, V.; et al. Human iPSC-derived iMSCs improve bone regeneration in mini-pigs. Bone 
Res. 2019, 7, 32. 
59. Spitzhorn, L.S.; Rahman, M.S.; Schwindt, L.; Ho, H.T.; Wruck, W.; Bohndorf, M.; Wehrmeyer, S.; Ncube, 
A.; Beyer, I.; Hagenbeck, C.; et al. Isolation and Molecular Characterization of Amniotic Fluid-Derived 
Mesenchymal Stem Cells Obtained from Caesarean Sections. Stem. Cells Int. 2017, 2017, 5932706. 
60. Timaner, M.; Tsai, K.K.; Shaked, Y. The multifaceted role of mesenchymal stem cells in cancer. Semin. 
Cancer Biol. 2020, 60, 225–237. 
61. Chun, S.J.; Rasband, M.N.; Sidman, R.L.; Habib, A.A.; Vartanian, T. Integrin-linked kinase is required for 
laminin-2-induced oligodendrocyte cell spreading and CNS myelination. J. Cell Biol. 2003, 163, 397–408. 
62. Silva, M.E.; Lange, S.; Hinrichsen, B.; Philp, A.R.; Reyes, C.R.; Halabi, D.; Mansilla, J.B.; Rotheneichner, P.; 
Guzman de la Fuente, A.; Couillard-Despres, S.; et al. Pericytes Favor Oligodendrocyte Fate Choice in 
Adult Neural Stem Cells. Front. Cell Neurosci. 2019, 13, 85. 
63. Jadasz, J.J.; Rivera, F.J.; Taubert, A.; Kandasamy, M.; Sandner, B.; Weidner, N.; Aktas, O.; Hartung, H.P.; 
Aigner, L.; Küry, P. p57kip2 regulates glial fate decision in adult neural stem cells. Development 2012, 139, 
3306–3315. 
64. Binder, M.D.; Cate, H.S.; Prieto, A.L.; Kemper, D.; Butzkueven, H.; Gresle, M.M.; Cipriani, T.; Jokubaitis, 
V.G.; Carmeliet, P.; Kilpatrick, T.J. Gas6 deficiency increases oligodendrocyte loss and microglial 
activation in response to cuprizone-induced demyelination. J. Neurosci. 2008, 28, 5195–5206. 
65. Tan, H.K.; Heywood, D.; Ralph, G.S.; Bienemann, A.; Baker, A.H.; Uney, J.B. Tissue inhibitor of 
metalloproteinase 1 inhibits excitotoxic cell death in neurons. Mol. Cell Neurosci. 2003, 22, 98–106. 
66. Figueres-Onate, M.; Garcia-Marques, J.; Lopez-Mascaraque, L. UbC-StarTrack, a clonal method to target 
the entire progeny of individual progenitors. Sci. Rep. 2016, 6, 33896. 
67. Schneider, C.A.; Rasband, W.S.; Eliceiri, K.W. NIH Image to ImageJ: 25 years of image analysis. Nat. 
Methods 2012, 9, 671–675. 
68. Schindelin, J.; Arganda-Carreras, I.; Frise, E.; Kaynig, V.; Longair, M.; Pietzsch, T.; Preibisch, S.; Rueden, 
C.; Saalfeld, S.; Schmid, B.; et al. Fiji: An open-source platform for biological-image analysis. Nat. Methods 
2012, 9, 676–682. 
69. Schira, J.; Gasis, M.; Estrada, V.; Hendricks, M.; Schmitz, C.; Trapp, T.; Kruse, F.; Kögler, G.; Wernet, P.; 
Hartung, H.P.; et al. Significant clinical, neuropathological and behavioural recovery from acute spinal 
cord trauma by transplantation of a well-defined somatic stem cell from human umbilical cord blood. 
Brain 2012, 135 Pt 2, 431–446. 
70. Schira, J.; Falkenberg, H.; Hendricks, M.; Waldera-Lupa, D.M.; Kögler, G.; Meyer, H.E.; Müller, H.W.; 
Stühler, K. Characterization of Regenerative Phenotype of Unrestricted Somatic Stem Cells (USSC) from 
Human Umbilical Cord Blood (hUCB) by Functional Secretome Analysis. Mol. Cell Proteom. 2015, 14, 2630–
2643. 
71. Schira, J.; Heinen, A.; Poschmann, G.; Ziegler, B.; Hartung, H.P.; Stühler, K.; Küry, P. Secretome analysis of 
nerve repair mediating Schwann cells reveals Smad-dependent trophism. FASEB J. 2019, 33, 4703–4715. 
72. Cox, J.; Michalski, A.; Mann, M. Software lock mass by two-dimensional minimization of peptide mass 
errors. J. Am. Soc. Mass Spectrom 2011, 22, 1373–1380. 
73. Tusher, V.G.; Tibshirani, R.; Chu, G. Significance analysis of microarrays applied to the ionizing radiation 
response. Proc. Natl. Acad. Sci. USA 2001, 98, 5116–5121. 
  
Int. J. Mol. Sci. 2020, 21, 4350 25 of 25 
 
74. Zhao, L.; Poschmann, G.; Waldera-Lupa, D.; Rafiee, N.; Kollmann, M.; Stuhler, K. OutCyte: A novel tool 
for predicting unconventional protein secretion. Sci. Rep. 2019, 9, 19448. 
75. Perez-Riverol, Y.; Csordas, A.; Bai, J.; Bernal-Llinares, M.; Hewapathirana, S.; Kundu, D.J.; Inuganti, A.; 
Griss, J.; Mayer, G.; Eisenacher, M.; et al. The PRIDE database and related tools and resources in 2019: 
Improving support for quantification data. Nucleic Acids Res. 2019, 47, D442–D450. 
 
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access 
article distributed under the terms and conditions of the Creative Commons Attribution 
(CC BY) license (http://creativecommons.org/licenses/by/4.0/). 
 
